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Objective : A retrospective review of premedication method and drug resist-
ance of aspirin and clopidogrel in association with thromboembolic events 
during and after coil embolization of an unruptured intracranial aneurysm 
was conducted.
Methods : Our premedication policy for coil embolization of an unruptured 
intracranial aneurysm has changed from administration of the loading 
dose before the procedure (i.e. loading group) to repeated administration 
of the maintenance dose for several days (i.e. preparation group). The 
loading group (27 patients with 29 aneurysms) and the preparation 
group (30 patients with 35 aneurysms) were compared for identification 
of the effect of premedication method on periprocedural thromboembolic 
events. The results of drug response assays of the preparation group 
were analyzed with respect to periprocedural thromboembolic events.
Results : No statistically significant difference in incidence of thromboem-
bolic events was observed between the loading group and the prepara-
tion group. Analysis of the results of the drug response assay showed 
high prevalence (56.7%, 73.3%) of clopidogrel resistance and relatively low 
prevalence (6.7%) of aspirin resistance. Patients who had thromboembolic 
events tended to have lower responsiveness to both aspirin and clopi-
dogrel than patients without it. 
Conclusion : The method of antiplatelet premedication does not affect the 
rate of periprocedural thromboembolic events in coil embolization for treat-
ment of an unruptured intracranial aneurysm. Nevertheless, considering 
the high prevalence of drug resistance, it is reasonable to premedicate an-
tiplatelet agents in the preparation method for the drug response assay. 
Use of a higher dose of aspirin and clopidogrel or addition of an alternative 
drug (cilostazol or triflusal) can be applied against antiplatelet agent 
resistance. However, because the hemorrhagic risk associated with this 
supplementary use of antiplatelet agent has not been well-documented, 
the hemorrhagic risk and the preventive benefit must be weighed.
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INTRODUCTION The incidence of overall complication during elec-
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tive coil embolization for treatment of unruptured 
aneurysms is low.26) Thromboembolic events account for 
the majority of complications, with a reported incidence of 
3.4-6.2%.7)11)27) Antiplatelet agent premedication has 
been proposed for reducing thromboembolic risk, and 
the current evidence supports this preventive usage.3)7)11) 
Aspirin and clopidogrel have been widely used for 
antiplatelet premedication for endovascular procedures.4) 
Responsiveness to both drugs is quite variable, and 
there is a group of patients who exhibit low re-
sponsiveness to these two drugs.11)21) Aspirin and clo-
pidogrel resistance have been known to show an as-
sociation with thromboembolic events during the en-
dovascular procedure.4)24) However, there is no gen-
eral consensus on defining aspirin and clopidogrel re-
sistance, which hinders investigation of the prevalence. 
Several studies have reported a prevalence of drug re-
sistance of 5.5-60% for aspirin and 5-44% for 
clopidogrel.4)5)25)
Two methods for premedicating antiplatelet agents 
have been used; one is dosing the drugs for several 
days until the steady drug level is achieved and the 
other is to load a high-dose of the drugs before the 
procedure. The former can be described as a ‘preparation 
method’, while the latter can be called a ‘loading 
method’. Little has been reported regarding the effects 
of these two premedication methods in the context of 
coil embolization for treatment of an unruptured 
aneurysm. In this study, we attempted to compare the 
difference in periprocedural thromboembolic events 
between the preparation method, in which patients 
take aspirin and clopidogrel for several days, and the 
loading method, in which patients take a high dose of 
aspirin and clopidogrel before the procedure.
Patients in the preparation group underwent drug 
response assays of clopidogrel and aspirin before the 
procedure. We analyzed the results of these drug re-
sponse assays in relation to the periprocedural throm-
boembolic events. Literature on antiplatelet agent re-
sistance was reviewed in the search for proper treat-
ment for aspirin and clopidogrel resistance.
MATERIALS AND METHODS
Subjects of this study underwent elective coil embo-
lization for treatment of an unruptured intracranial 
aneurysm from January 2011 to June 2012. Our policy 
on antiplatelet agent premedication had changed from 
the loading method to the preparation method by the 
end of December 2011. In the loading method, 162 mg 
of aspirin and 300 mg of clopidogrel were administered 
orally on the day before the coil embolization procedure. 
In the preparation method, 81 mg of aspirin and 75 
mg of clopidogrel were given per os in the morning 
for five days before the coil embolization procedure. 
On the day of coil embolization, 81 mg of aspirin and 
75 mg of clopidogrel were given to all patients re-
gardless of the premedication method. Patients were 
designated to either the ‘Loading group’ or the 
‘Preparation group’ according to their method of tak-
ing antiplatelet agent before coil embolization. This 
designation was done in a consecutive manner.
In order to rule out the risk of stent insertion per se, 
patients who underwent stent-assisted coil emboliza-
tion were excluded. Because it could be a significant 
independent risk factor, patients with a history of is-
chemic stroke and/or a higher than moderate degree 
of stenosis in any of the intracranial arteries and car-
otid arteries were also excluded. There were two in-
tra-procedural ruptures of aneurysm, which were ex-
cluded, considering that vasospasm could be an inter-
fering factor. Patients in both groups who were on 
antiplatelet therapy other than aspirin and clopidogrel 
were excluded, and, in order to avoid compounding 
by existing antiplatelet effects, patients who were al-
ready on aspirin, clopidogrel, or both were excluded 
from the loading group. Ultimately, 30 patients with 
35 intracranial aneurysms were included in the prepa-
ration group, and 27 patients with 29 aneurysms were 
included in the loading group.
Thromboembolic events were categorized according 
to either radiological events or symptomatic events. 
Thrombus formation during the procedure, or any 
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Preparation group (n = 30) Loading group (n = 27) p value
1. Demographics
Age
Female(Ratio)
Comorbidity
DM
Dyslipidemia
Hypertension
  57.6 (± 10.3)
23 (76.7%)
 4 (13.3%)
 3 (10.0%)
10 (33.3%)
  57.9 (± 9.8)
 19 (70.4%)
  6 (22.2%)
  2 ( 7.3%)
 13 (48.1%)
0.827
0.590
0.492
1.000
0.255
2. Aneurysm-related factors
Size(mm)
Location
ICA
ACA
MCA
Posterior circ.
Neck:Dome ratio
     4.34 (±1.33)
 21 (60.0%)
  6 (17.1%)
  8 (22.9%)
  0 ( 0%)
     1.50 (± 0.39)
    4.13 (± 1.29)
 16 (55.2%)
  5 (17.2%)
  6 (20.7%)
  2 ( 6.9%)
    1.49 (± 0.40)
0.604
0.697
1.000
0.835
1.000
0.854
3. Procedure-related factors
Technique
Conventional
Double-catheter
Balloon-assisted
Degree of embolization
Complete
Near complete
Partial
Coil protrusion
  7 (20.0%)
  9 (25.7%)
 19 (54.3%)
  7 (20.0%)
 27 (77.9%)
  1 ( 2.9%)
  1 ( 2.8%)
 13 (44.8%)
  5 (17.2%)
 11 (37.9%)
 11 (37.9%)
 18 (62.1%)
   0
  1 ( 4.0%)
0.057
0.547
0.218
0.163
0.272
1.000
1.000
DM = diabetes mellitus; ICA = internal carotid artery; MCA = middle cerebral artery; circ. = circulation.
Table 1. Basic characteristics of the study population
acute infarct on postoperative magnetic resonance im-
ages (MRI) were defined as radiological events. In the 
case of intraprocedural thrombus formation, glyco-
protein IIb/IIIa inhibitor was administered through 
an intra-arterial route in all cases. Postoperative MRI 
was taken when there were any intraprocedural 
events, such as coil loop protrusion or any other sus-
picion of thromboembolism on the angiography. 
Symptomatic events were defined as any occurrence 
of newly-developed neurologic deficit or cerebral in-
farct-related symptoms, including lethargy, headache, 
dizziness and/or nausea after the coil embolization 
procedure. Visual impairment due to retina ischemia 
was also regarded as neurologic deficit. Patients who 
exhibited both symptoms and radiological finding of 
a thromboembolic event were regarded as having a 
symptomatic event.
In the preparation group, drug response assays for 
aspirin and clopidogrel were performed using the 
VerifyNow® system (Accumetrics, San Diego, CA). 
Aspirin reaction unit (ARU) was measured by 
VerifyNow® Rapid platelet function assay-aspirin 
(RPFA-ASA). P2Y12 reaction unit (PRU) and platelet 
inhibition rate were obtained from the VerifyNow® 
P2Y12 assay. Aspirin resistance was defined as ARU 
> 550 and clopidogrel resistance was defined as PRU 
> 230 or platelet inhibition rate < 20% referring to the 
manufacturer. When antiplatelet resistance was con-
firmed, either 600 mg of triflusal or 200 mg of cil-
ostazol was administered before the coil embolization 
procedure. For administration of an alternative drug, 
platelet inhibition rate < 20% was used as the criteria 
for clopidogrel resistance.
SPSS version 16 for Windows (SPSS Inc, Chicago, 
IL) was used for statistical analysis. Continuous data 
were presented as mean ± standard deviation (SD) 
and were compared using the Mann-Whitney test. 
Fisher’s exact test or chi-square test was used for 
processing of categorical data. Statistical significance 
was defined as ‘p < 0.05’.
RESULTS
A summary of the basic characteristic of patients 
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Preparation group (n = 30) Loading group (n = 27) p value
Intraprocedural event
Symptomatic event
Overall event
  2 (6.7%)
3 (10.0%)
5 (16.7%)
4 (14.8%)
 1 (3.7%)
5 (18.5%)
0.408*
0.613*
 0.854†
*Fisher's exact test
†Chi-square test
Table 2. Incidence of thromboembolic event and comparison between two groups
Prevalence
Aspirin resistance*
Suboptimal response†
Clopidogrel resistance
Inhibition rate‡
P2Y12 reaction unit§
Aspirin and Clopidogrel resistance
Including suboptimal response
 2 ( 6.7%)
 3 (10.0%)
 17 (56.7%)
 22 (73.3%)
 2 ( 6.7%)
 4 (13.3%)
*Aspirin reaction unit(ARU) above 550 was used as the criteria.
†ARU between 500 and 550 was used as the criteria.
‡Inhibition rate below 20% was used at the criteria.
§P2Y12 reaction unit(PRU) above 230 was used as the criteria.
Table 3. Results of the response assay of aspirin and clopidogreland aneurysms, and the results of coil embolization is 
shown in Table 1. No significant differences were not-
ed in demographics, aneurysmal factors, and proce-
dure-related factors. Mean age was 57.6 (± 10.3) years 
old in the preparation group and 57.9 (± 9.8) years 
old in the loading group. Female predominance was 
observed in both groups. Aneurysm size was 4.34 (± 
1.33) mm in the preparation group and 4.13 (± 1.29) 
mm in the loading group. Neck: Dome ratios were 
similar in both groups. The most common location of 
the aneurysm was the ICA, followed by the MCA, in 
both groups, and ICA aneurysms consisted of more 
than half of all aneurysms. Although the difference 
was not statistically significant, more aneurysms were 
treated by a balloon-assisted technique in the prepara-
tion group, while more aneurysms were embolized by 
a conventional technique in the loading group. Most 
coil embolizations were either complete or near com-
plete, with minimal neck remnant; 97.1% and 100% in 
the preparation group and the loading group, respectively.
The incidences of both radiological thromboembolic 
events and symptomatic thromboembolic events did 
not differ significantly between the preparation group 
and the loading group (Table 2). The overall incidence 
of thromboembolic events did not differ significantly, 
either. More symptomatic evens were observed in the  
preparation group, while more radiological events 
were observed in the loading group. Symptomatic 
events included blurred vision by either retina ische-
mia or cerebral infarct in the occipital lobe, mild 
weakness of the unilateral lower extremity without 
functional difficulty, and disequilibrium. There were 
four cases of thrombus formation detected on angiog-
raphy after completion of coil packing. All thrombi 
were lyzed after intra-arterial administration of glyco-
protein IIb/IIIa inhibitor, and the patency of the involved 
artery was maintained on the delayed angiography.
A summary of the results of antiplatelet response 
assays is shown in Table 3. Although the prevalence 
of aspirin resistance was 6.7%, the prevalence of clo-
pidogrel resistance was remarkably high (56.7%, 73.3%). 
Every patient with aspirin resistance also showed re-
sistance to clopidogrel. Suboptimal response to aspir-
in, which can be estimated from ARU ranging be-
tween 500 and 550, was found in three patients and 
two of them also had low responsiveness to clopidogrel. 
Results of analysis of the relationship between the 
thromboembolic event and responsiveness to aspirin 
and clopidogrel are shown in Table 4. Patients who 
had a thromboembolic event had higher ARU than pa-
tients who did not have a thromboembolic event 
[520.0 (± 45.8) vs. 426.3 (± 44.3)], which was statisti-
cally significant (p = 0.002). In addition, a statistically 
significant difference (p = 0.032) in the results of re-
sponse assay of clopidogrel was observed between the 
two groups [358.6 (± 28.2) vs. 283.4 (± 80.5)]. According 
to the results, suboptimal response to aspirin, includ-
ing overt resistance, in particular, showed a strong re-
lationship with thromboembolic events.
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Control group 
(n = 25)
Thromboembolism 
group (n = 5) p value
Aspirin
(ARU)
Clopidogrel
(PRU)
426.3 (± 44.3)
283.4 (± 80.5)
520.0 (± 45.8)
358.6 (± 28.2)
0.002
0.032
ARU = aspirin reaction unit; PRU = P2Y12 reaction unit
Table 4. Comparison of drug responsiveness between patients
with and without thromboembolic event
DISCUSSION
As a supplement to intraprocedural anticoagulation, 
which has been almost standardized in all types of 
coil embolization-related procedures for thromboem-
bolic risk reduction, premedication with antiplatelet 
agent has at first been adopted to the stent-assisted 
coil embolization from coronary stenting, considering 
its beneficial effects.3) As a result of the marked re-
duction of thromboembolic complications in stent-as-
sisted coil embolization, usage of premedication with 
an antiplatelet agent has spread to other modes of coil 
embolization.3) Successive studies have also demon-
strated the efficacy of antiplatelet premedication for 
the multi-catheter technique for coil embolization.7)11) 
So far, the efficacy of premedication with an anti-
platelet agent for balloon-assisted coil embolization 
has not been well demonstrated. Layton et al. re-
ported a positive reduction of the rate of thromboem-
bolic complication by clopidogrel premedication in a 
population in which 33% (73 of 221) of patients un-
derwent balloon-assisted coil embolization.13) Since us-
age of antiplatelet agents has become widespread, 
there has been a concern about the increment of hem-
orrhagic complications. However, previous studies 
have coherently reported that the rate of hemorrhagic 
event is not altered by antiplatelet premedication.16)27) 
In short, the benefit of antiplatelet premedication in 
the conventional coil embolization has not been 
proved; therefore, since it cannot be fully estimated 
before the procedure whether conventional coil embo-
lization will be possible and the complication rate of 
antiplatelet agent premedication is acceptably low, it 
is reasonable to premedicate the entire population of 
patients undergoing coil embolization.7)11)
In our institute, due to concerns regarding hemor-
rhagic events, which can be fatal with high frequency, 
there was a reluctance to employ antiplatelet agent 
before the endovascular procedures. We began anti-
platelet agent premedication with the stent-assisted 
coil embolization. We only employed antiplatelet 
agent for stent-assisted procedures and aspirin with 
clopidogrel was given orally for three days before the 
procedure, referring to the guideline report of stent-as-
sisted coil embolization.1) Individual variability of re-
sponsiveness to antiplatelet agents has been reported 
and the duration of antiplatelet premedication for 
stent-assisted coil embolization has been extended to 
five days with carefulness concerning about the hemor-
rhagic risk.4)20)25) After going through serial throm-
boembolic events and perceiving the low risk of hem-
orrhage related to antiplatelet agents, we began use of 
antiplatelet agent for other modes of coil emboliza-
tion, which include the conventional method, multiple 
catheter technique, and balloon-assisted procedures.7)11)13) 
The length of time during which platelet function is 
compromised can be recognized as a cumulative risk 
for hemorrhagic event in patients with intracranial 
aneurysm. In order to minimize the duration of ex-
posing patients to compromised platelet aggregation, we 
first employed antiplatelet agents using the loading 
method. Then, resistance to antiplatelet agents became 
an issue; therefore, we changed our policy of anti-
platelet agent premedication to the preparation meth-
od, which was adopted from that of stent-assisted coil 
embolization. In this way, using the drug response as-
says, we were able to screen out patients with resist-
ance to antiplatelet agents, and deal with the risk.
Antiplatelet effect of aspirin and clopidogrel loading 
has been established in in vivo laboratory studies. A 
sufficient antiplatelet effect was achieved 12 hours af-
ter loading of aspirin 200 mg.17) A single dose of clo-
pidogrel between 300 mg and 400 mg inhibited plate-
let aggregations at the same level as the steady state 
of daily medication by two hours after loading.22) 
However, little has been reported in relation to com-
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parison of clinical results from use of the methods of 
antiplatelet agent therapy initiation, and, to the best 
of our knowledge, no study comparing the effect of 
high-dose loading of antiplatelet agents and the effect 
of repeated dosing for the steady state has been re-
ported in the literature on coil embolization.
We compared clinical results of antiplatelet agent 
premedication according to the rate of periprocedural 
thromboembolic events. No statistically significant dif-
ference was observed between the loading group and 
the preparation group. This result is consistent with 
findings of previous in vivo laboratory studies.17)22)24) 
Although no statistical difference was observed be-
tween the two groups, the proportion of conventional 
coil embolization in the loading group was more than 
double that in the preparation group. Considering 
this subtle heterogeneity, there is a possibility that the 
preparation method may have more efficacies since 
the double-catheter technique and balloon-assisted 
technique are regarded as being prone to end in 
thromboembolism. Further studies comparing the 
methods of premedication with a larger population 
are called for. 
Antiplatelet agent resistance is a known risk factor 
for thromboembolic complication.4)22)23) In this study, 
the he prevalence of aspirin resistance was analogous 
to the prevalence found in previous reports.4)22)23) On 
the other hand, the prevalence of clopidogrel resist-
ance was very high and was above the range of prev-
alence that has been reported in the literature. Poor 
compliance or underdosing can be inferred as the ex-
planation for this result. It should be emphasized that 
the duration of premedication could have been 
inadequate. According to previous reports, clopidog-
rel requires three to seven days to achieve the steady 
state for antiplatelet action.4)22) Due to concerns about 
the hemorrhagic risk, we prescribed only five days of 
clopidogrel; this could be the reason for higher preva-
lence of clopidogrel resistance. Although aspirin re-
sistance was relatively low, compared with the pre-
vious reports, aspirin also requires four to seven days 
to achieve the steady state by daily dose.2)4) Although 
not detected for either suboptimal response or overt 
resistance, some patients may have had a lesser re-
sponse to aspirin due to the shortage of dosing 
duration. What can be drawn from these findings is 
that prescribing seven days of aspirin and clopidogrel 
for premedication in the context of the prevention of 
thromboembolic events seems to be proper since the 
drug action will be optimal for more patients in this 
way. Nevertheless, this inherently increases the risk of 
hemorrhagic events as much as lengthened time of 
premedication. More evidence supporting the ex-
tended duration of antiplatelet agent premedication is 
required before making a recommendation.
We observed a tendency of low responsiveness to 
both aspirin and clopidogrel in patients who had 
thromboembolic events. This is consistent with pre-
vious reports addressing the risk of antiplatelet 
resistance.4)11)24)25) According to the results of the as-
pirin response assay and analysis with aspects to 
thromboembolic risk, not only overt resistance to the 
drug but also suboptimal response to the drug was 
reported as a significant risk factor for the throm-
boembolic event described in our study. However, be-
cause all of the patients with aspirin resistance and 
two of three patients with suboptimal response to as-
pirin had concurrent clopidogrel resistance, we cannot 
conclude that suboptimal response and resistance to 
aspirin alone is a strong risk factor. It shall be proper 
to conclude that co-existing clopidogrel resistance and 
suboptimal response to aspirin, including overt resist-
ance, is a strong risk factor for thromboembolic event. 
Several methods for management of antiplatelet re-
sistance have been proposed; 1) addition of anti-
platelet agents of alternative molecular target, 2) us-
ing a higher dose of aspirin and clopidogrel, 3) drug 
for the same molecular target but metabolized by oth-
er pathways and 4) active-form drug.25) Some studies 
have reported that use of a higher dose of either as-
pirin or clopidogrel reduces the prevalence of anti-
platelet agent resistance.4)20)25) They have also con-
cordantly reported that the hemorrhagic risk did not 
differ between the regular dosing group and the high-
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er dosing group. When the high risk of thromboem-
bolic event due to drug resistance is expected, such as 
concurrent resistance to both aspirin and clopidogrel, 
it is practical to give a higher dose of aspirin, clopi-
dogrel, or both. The optimal dosage of aspirin and 
clopidogrel in cases of drug resistance has not been 
studied in the population of patients undergoing coil 
embolization. According to previous studies on clopi-
dogrel, patients loaded with 600 mg showed less 
prevalence of drug resistance than patients loaded 
with 300 mg, while the higher doses were not more 
effective and the maintenance dose of 150 mg brought 
about less frequent drug resistance than maintaining 
75 mg.4)20) For aspirin, the effectiveness increased until 
the maintenance dosage reached 325 mg, while the 
higher dose was not more effective.2)4) To sum up, 
doubling the dosage of antiplatelet agent can be con-
sidered against drug resistance. When it comes to pre-
medication for elective coil embolization, this dou-
bling of dosage can be actualized by giving the load-
ing dose additionally before the procedure since the 
time between the point of detection of drug resistance 
and the schedule for coil embolization is usually 
short, one or two days.
To date, the first solution mentioned above has had 
the most robust background; triple therapy with tri-
flusal or cilostazol showed superb clinical results, 
compared with dual antiplatelet therapy with aspirin 
and clopidogrel.9)10)23) In addition, when used as a tri-
ple therapy, these two drugs did not increase hemor-
rhagic risk.9)10)23) Cilostazol showed an even better 
outcome than a higher dose of clopidogrel.9)10) Both 
triflusal and cilostazol showed efficacy in prevention 
of ischemic stroke.15)18) They have also shown efficacy 
by loading dosage.8)14) These make cilostazol and tri-
flusal suitable for coping with aspirin and/or clopi-
dogrel resistance that appear in patients scheduled for 
any mode of coil embolization. Nonetheless, because 
the hemorrhagic risk of triple antiplatelet agent usage 
has not been elucidated in the context of coil emboli-
zation, for now, we cannot make any succinct 
recommendations. One can try adding cilostazol or 
triflusal when the risk of thromboembolic event is 
substantial since reports on coronary stenting have 
advocated the use of triple antiplatelet agents with 
addition of one of these two drugs. In our study, 
there were 17 patients whose resistance to aspirin, 
clopidogrel, or both was detected by using the 
VerifyNow® system. After confirming the resistance, 
we prescribed the loading dosage of either cilostazol 
or triflusal; ten patients with cilostazol and seven pa-
tients with triflusal. Although there was one case of 
mild gingival bleeding, due a to small number of cas-
es, we did not deduce any statistically meaningful 
information. Conduct of further studies of the efficacy 
in thromboembolic risk reduction and increment of 
hemorrhagic risk of triple antiplatelet agent therapy 
using cilostazol or triflusal in a larger population is 
needed.
Our study encompassed a small population with 
low incidence of the event. Power of statistical testing 
is an inevitable shortcoming of this study. Based on 
analysis of this study, repeated study with a larger 
population may demonstrate superiority of the prepa-
ration method. Some records on hemorrhagic events, 
including groin hematoma, gingival bleeding, or 
bruises were omitted; therefore, we did not evaluate 
hemorrhagic events. This is another weakness of this 
study. Further study should cover periprocedural 
hemorrhagic events, especially those associated with 
the extended administration and the higher dosage of 
aspirin and clopidogrel, and triple antiplatelet therapy 
with addition of cilostazol or triflusal. Finally, because 
we did not obtain postoperative MRI in all patients 
due to the problem of insurance coverage, our study 
had limitation in over determining radiologic throm-
boembolic events. A few radiological thromboembolic 
events may have gone undetected. 
CONCLUSION
The method used for premedication with an anti-
platelet agent does not affect the clinical result in terms 
of the rate of thromboembolic events. Nevertheless, 
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considering the high prevalence of resistance to aspir-
in and clopidogrel, it is still reasonable to premedicate 
with antiplatelet agents in the preparation method for 
drug response assays. Treatment of patients who ex-
hibit low responsiveness to both aspirin and clopidog-
rel (i.e. concurrent drug resistance) is important, as 
the thromboembolic risk is high in this group. Use of 
a higher dose of aspirin and clopidogrel or addition 
of an alternative drug (cilostazol or triflusal) can be 
applied against antiplatelet agent resistance. However, 
because the hemorrhagic risk associated with this 
supplementary use of antiplatelet agent has not been 
well-documented, the hemorrhagic risk and the pre-
ventive benefit must be weighed.
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